3rd International HIV/Viral Hepatitis Co-Infection Meeting
HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access
17 July 2016, Durban, South Africa

  • Overview
  • Organizing Committee
  • Partners
  • Programme
  • Poster Abstracts

The 3rd International HIV/Viral Hepatitis Co-Infection Meeting, hosted by the International AIDS Society (IAS), took place just prior to the 21st International AIDS Conference (AIDS 2016) and was held on 17 July, 2016 in Durban, South Africa (Durban ICC, Hall 2D/E, SR8).

The recent development of highly effective antiviral therapy for HBV and HCV provides the opportunity to counter the rising burden of chronic liver disease among people living with HIV. Global antiretroviral therapy scale-up should limit HBV‐related liver disease, through dual antiviral activity. Furthermore, development of antiretroviral therapy delivery infrastructure should enhance implementation of interferon-free DAA regimens for HCV once available. The focus of the meeting will be to identify challenges and opportunities for increasing the diagnosis and treatment of viral hepatitis in HIV infected persons, particularly in low and middle-income settings.

The 3rd International HIV/Viral Hepatitis Co-Infection Meeting fills a void in the landscape of meetings providing a unique opportunity for industry, academic, community and governmental stakeholders to interact and develop constructive solutions together that can support equitable access to modern therapeutics while maintaining sustainable innovation. The conference will provide research-based evidence to demonstrate the value of these curative therapies and will engage policy makers towards creating an environment that supports their wider therapeutic access nationally and internationally.

Meeting objectives

  1. To review the latest therapeutic developments in viral hepatitis B and C
  2. To identify challenges and successes in scaling up diagnosis, screening, antiviral treatment and prevention of viral hepatitis in HIV co-infected persons
  3. To identify how to optimize outcomes and costs to achieve sustainable and equitable access to these therapies globally
  4. To learn from successful models, such as novel voluntary licensing agreements and map a path toward scaling up of viral hepatitis treatment programmes in low-, middle- and high-income settings
  5. To advance the agenda for viral hepatitis eradication by assembling key stakeholders for a face-to-face discussion of major barriers and solutions.

Marina Klein
McGill University;
CIHR Canadian HIV Trials Network (CTN)
Montreal, Canada
Wendy Spearman
University of Cape Town
Cape Town, South Africa
Monique Andersson
Stellenbosch University, Faculty of Health Sciences
Stellenbosch, South Africa
Convener of HBV prevention and management theme
Isabelle Andrieux-Meyer
Geneva, Switzerland
Co-convener of HCV and HBV access theme
Anchalee Avihingsanon
Bangkok, Thailand
Co-convener of Epidemiology and disease burden theme
Sanjay Bhagani
Royal Free Hospital
London, UK
Co-convener of complex issues in HCV and HBV theme
Christoph Boesecke
University of Bonn
Bonn, Germany
EACS Liaison
Laurent Castera
Hôpital Beaujon
Paris, France
EASL Liaison
Curtis Cooper
CIHR Canadian HIV Trials Network (CTN)
Ottawa, Canada
Co-convener of HCV therapeutic development theme
Greg Dore
Kirby Institute, University of New South Wales
Sydney, Australia
Convener of treatment in special populations theme
Jordan Feld
University of Toronto
Toronto, Canada
Convener of HBV therapeutic development
Karine Lacombe
Hôpital Saint-Antoine
Paris, France
Convener of Epidemiology and disease burden theme
Gail Matthews
Kirby Institute, University of New South Wales
Sydney, Australia
Convener of complex issues in HCV and HBV theme
Sébastien Morin
International AIDS Society
Geneva, Switzerland
Point contact for coordination with the IAS and AIDS2016
Marion Peters
University of California
San Francisco, USA
Co-convener of HBV therapeutic development theme
Jürgen Rockstroh
University of Bonn
Bonn, Germany
Convener of treatment in special populations theme
Mark Sulkowski
Viral Hepatitis Center, John Hopkins
Baltimore, USA
Convener of HCV therapeutic development theme
Tracy Swan
MSF Access Campaign
New York, USA
Convener of HCV and HBV access theme


Topic: HBV Epidemiology and Outcomes (Authors to present 11:00-11:30)

Presenting author
Affiliation & Country
Abstract Title
M.G. Kouamé, R. Moh, A. Boyd, A. Badjé, D. Gabillard, J.B. N'takpé, S. Maylin, S.P. Eholié, X. Anglaret, C. Danel
Programme PAC-CI, ANRS Research Site
Cote D'Ivoire
Higher mortality in HIV-HBV co-infected persons with elevated HBV replication in the Temprano Trial
T. Maponga, H. Vermeulen, B. Robertson, S. Burmeister, W. Preiser, M. Kew, M. Andersson
University of Stellenbosch
South Africa
The effect of HIV infection on the age at presentation of HBV-driven hepatocellular carcinoma in South Africa
M. Vinikoor, E. Sinkala, R. Chilengi, L. Mulenga, B. Chi, Z. Zyambo, C. Hoffmann, M.-A. Davies, M. Egger, G. Wandeler
University of Alabama at Birmingham
Impact of antiretroviral therapy on liver stiffness among Zambian adults with HIV-HBV co-infection and HIV mono-infection
M. Anderson, S. Gaseitsiwe, S. Moyo, K.P. Thami, T. Mohammed, D. Setlhare, T.K. Sebunya, E.A. Powell, J. Makhema, J.T. Blackard, R. Marlink, M. Essex, R.M. Musonda
Botswana Harvard AIDS Institute Partnership
Response to Truvada based cART in HIV/HBV co-infected patients in Botswana
T. Maponga, M. Andersson, J. Taaljaard, C.J. Van Rensburg, W. Preiser, R. Glashoff
University of Stellenbosch
South Africa
Improved liver fibrosis scores in treated HBV/HIV co-infected patients in South Africa despite persistent immune dysregulation

Topic: HCV Epidemiology and Natural History (Authors to present 12:30-13:00)

Presenting author
Affiliation & Country
Abstract Title
D. van Santen, J. van der Helm, G. Touloumi, N. Pantazis, R. Muga, B. Bartmeyer, J. Gill, E. Sanders, A. Kelleher, R. Zangerle, C. Béguelin, K. Porter, M. Prins, R. Geskus
Public Health Service of Amsterdam
Effect of the timing of hepatitis C virus infection, relative to HIV seroconversion on CD4 T cell and HIV RNA evolution among HIV-positive MSM
A. De Weggheleire, S. An, I. De Baetselier, S. Teav, V. So, S. Sea, S. Ros, S. Thai, S. Francque, L. Lynen
Institute of Tropical Medicine
Hepatitis C prevalence, viral diversity and severity of liver disease in HIV patients in Phnom Penh, Cambodia
V. Sapsirisavat, A. Avihingsanon, D. Trachunthong, S. Kerr, J. Jantarapakde, S. Pengnonyang, S. Jitjang, R. Janamnuaysook, P. Mingkwanrungrueng, J. Ohata, A. Sohn, A. Katz, N. Phanuphak
Thai Red Cross AIDS Research Centre
Extremely low hepatitis C antibody prevalence among high-risk, HIV-positive and HIV-negative men who have sex with men and transgender women from community-based organizations in Thailand

Topic: HCV Testing, Monitoring and Management (Authors to present 13:00-13:30)

Presenting author
Affiliation & Country
Abstract Title
A.M. Newsum, I.G. Stolte, J.T.M. van der Meer, J. Schinkel, M. van der Valk, J.W. Vanhommerig, A. Buvé, M. Danta, A. Hogewoning, M. Prins
Public Health Service of Amsterdam
Development and validation of a risk score to assist testing for acute HCV infection in HIV-infected MSM
M. Nelson, S. Bhagani, R.H. Hyland, C. Yun, M. Mertens, A. Jackson, W. Zheng, D.M. Brainard, J.G. Mchutchinson, P. Ingliz, T. Lutz, J.K. Rockstroh
Chelsea and Westminster Hospital
United Kingdom
Ledipasivr/Sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection
A. Luetkemeyer, C. Cooper, S. Naggie, M. Saag, D. Dieterich, M. Sulkowski, S. Naik, M. Natha, J. Yang, L. Stamm, H. Dvory-Sobol, I. Walker, J. McHutchison
Gilead Sciences
United States
Retreatment of HCV/HIV co-infected patients who failed 12 weeks of LDV/SOF
G. Matthews, J. Neuhaus, J. Rockstroh, L. Peters, F. Gordin, A. Arenas-Pinto, C. Emerson, K. Marks, J. Hidalgo, R. Castro, C. Stephan, N. Kumarasamy, S. Emery
University of Bonn
Non-invasive serum markers suggest benefit for early ART initiation on liver fibrosis progression within the START study
C. Boesecke, G.J. Singh, S. Scholten, T. Lutz, A. Baumgarten, S. Schneeweiss, A. Trein, M. Rausch, P. Ingiliz, J.K. Rockstroh, M. Nelson
Bonn University Hospital
Telaprevir containing triple therapy in acute HCV co-infection: the CHAT study
M. Sulkowski, K. Agarwal, K. Patel, D. Samuel, M. Bourlière, Z. Younes, T. Morgan, S. Strasser, B. Leggett, S. Naik, B. Collins, M. Natha, L. Liu, X. Ding, J. Mcnally, A. Osinusi, D.M. Brainard, J. McHutchison, N. Afdhal, I. Walker, N. Brau
Gilead Sciences
United States
SOF/VEL for 12 weeks results in high SVR12 rates in subjects with negative predictors of response to treatment: an integrated analysis of efficacy from the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies

Topic: HCV Treatment Access (Authors to present 15:30-16:00)

Presenting author
Affiliation & Country
Abstract Title
M. Hellard, N. Scott, E. Mcbryde, A. Thompson, J. Doyle
Burnet Institute
Treatment scale-up in Australia to achieve global hepatitis C virus incidence and mortality elimination targets: a cost-effectiveness model
D. Gotham, M. Barber, J. Fortunak, A. Pozniak, A. Hill
Imperial College London
United Kingdom
Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access
J. Bruneau, D. Jutras-Aswad, G. Zang, É. Roy
Université de Montréal
Exposure to various combinations of Harm reduction strategies in relation to HIV and HCV incidences among PWID in Montreal, Canada
N. Harris, T. Wilder, K. McKinnon, S.H. Kim, A. Urbina
Mount Sinai Health System
United States
Increasing HCV Access through Clinical Education: Medical Provider Knowledge and Practice Change Intentions
D. Simões, R. Freitas, B. dos Santos, R. Fuertes, L. Mendão
GAT - Grupo de Ativistas em Tratamentos
Community engagement in universal access to DAA hepatitis C treatment: the Portuguese case